Remotiv – Ze 117

What is depression?

In typical depressive episodes the individual usually suffers from depressed mood, loss of interest and enjoyment, and reduced energy leading to increased fatiguability and diminished activity. Marked tiredness after only slight effert is common. The lowered mood varies little from day to day, and is often unresponsive to circumstances, yet may show a characteristic diurnal variation as the day goes on.
The underlying mechanisms leading to depression focus on a reduced level of neurotransmitters such as serotonin, noradrenaline and dopamine, which are present in the brain and assist communication between neuronal cells.


Remotiv – Ensuring a natural balance

Treatment of symptoms in mild to moderate depressive disorders (F32.0 und F32.1 according to ICD-10). Depressed mood, fluctuation of mood, inner restlessness, anxiety, states of tension including the related disorders of falling and remaining asleep.


Specific extract Ze 117
Ze 117 is a quantified extract from the aerial plant parts of St. John’s wort (Hypericum perforatum L.), harvested during the flowering period and cultivated by Zeller in various countries. The cultivation, harvesting, drying, storage and delivery of the herbal substance is performed in accordance with the current guideline on good agricultural and collection practice (GACP) for starting materials of herbal origin. Ze 117 quality is validated in various tests, i.e. tests on inorganic impurities (such as heavy metals like lead, cadmium and mercury), tests on microbiological quality, and tests on pesticides and mycotoxins. The range of testing is state of the art for this type of herbal substance. Test procedures are performed by Zeller and by specialized external laboratories appointed by Zeller.


Evidence based phyto-therapy – Key studies

Studies ZE 117

Studies ZE 117


Ze 117 shows triple action on presynaptic neurons


Ruedeberg, C. et al. Phytother. Res. (2010); 24: 249-251
Kientsch et al. Pharmacopsychiatry (2001); 34: 56-60




  • Remotiv shows very low hyperforin levels (< 1% hyperforin) and, therefore, a reduced risk of CYP3A4 and P-gp mediated drug-drug interactions.
  • Remotiv fulfills the requirements of well-established use of the European Medicines Agency (EMA).
  • The superiority of Remotiv against placebo and the non-inferiority against imipramine as well as fluoxetine (therapeutically equivalent) has been demonstrated and was confirmed by EMA assessment report.